Pharmacogenetics of cytotoxic drugs

Expert Rev Anticancer Ther. 2001 Aug;1(2):301-8. doi: 10.1586/14737140.1.2.301.

Abstract

The main genetic polymorphisms affecting the metabolism and transport of cytotoxic drugs are discussed in this review. Likely future approaches to pharmacogenetics and emerging technologies, such as tumor classification using microarray analysis, are also considered.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / metabolism*
  • Antineoplastic Agents / pharmacology*
  • Arylamine N-Acetyltransferase / genetics
  • Arylamine N-Acetyltransferase / metabolism
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P-450 Enzyme System / metabolism
  • Cytotoxins / metabolism*
  • Cytotoxins / pharmacology*
  • Dihydropyridines / metabolism
  • Glucuronosyltransferase / genetics
  • Glucuronosyltransferase / metabolism
  • Humans
  • Methyltransferases / genetics
  • Methyltransferases / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology
  • Neoplasms / genetics*
  • Neoplasms / metabolism
  • Oxidoreductases / genetics
  • Oxidoreductases / metabolism
  • Pharmacogenetics*
  • Polymorphism, Genetic / genetics*

Substances

  • Antineoplastic Agents
  • Cytotoxins
  • Dihydropyridines
  • 1,4-dihydropyridine
  • Cytochrome P-450 Enzyme System
  • Oxidoreductases
  • Methyltransferases
  • thiopurine methyltransferase
  • Arylamine N-Acetyltransferase
  • Glucuronosyltransferase